Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Christine Walsh to Neoplasm Recurrence, Local

This is a "connection" page, showing publications Christine Walsh has written about Neoplasm Recurrence, Local.

 
Connection Strength
 
 
 
0.569
 
  1. Walsh CS, Kamrava M, Rogatko A, Kim S, Li A, Cass I, Karlan B, Rimel BJ. Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer. PLoS One. 2021; 16(6):e0252665.
    View in: PubMed
    Score: 0.132
  2. Walsh C. Targeted therapy for ovarian cancer: the rapidly evolving landscape of PARP inhibitor use. Minerva Ginecol. 2018 Apr; 70(2):150-170.
    View in: PubMed
    Score: 0.102
  3. Cohen JG, Tran AQ, Rimel BJ, Cass I, Walsh CS, Karlan BY, Li AJ. Thrombocytosis at secondary cytoreduction for recurrent ovarian cancer predicts suboptimal resection and poor survival. Gynecol Oncol. 2014 Mar; 132(3):556-9.
    View in: PubMed
    Score: 0.079
  4. Zakhour M, Li AJ, Walsh CS, Cass I, Karlan BY, Rimel BJ. Post treatment surveillance of type II endometrial cancer patients. Gynecol Oncol. 2013 Dec; 131(3):609-12.
    View in: PubMed
    Score: 0.077
  5. Diaz ES, Walts AE, Karlan BY, Walsh CS. Venous thromboembolism during primary treatment of ovarian clear cell carcinoma is associated with decreased survival. Gynecol Oncol. 2013 Dec; 131(3):541-5.
    View in: PubMed
    Score: 0.077
  6. Fleming ND, Cass I, Walsh CS, Karlan BY, Li AJ. CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol. 2011 May 01; 121(2):249-52.
    View in: PubMed
    Score: 0.064
  7. Hodeib M, Cohen JG, Mehta S, Rimel BJ, Walsh CS, Li AJ, Karlan BY, Cass I. Recurrence and risk of progression to lower genital tract malignancy in women with high grade VAIN. Gynecol Oncol. 2016 06; 141(3):507-510.
    View in: PubMed
    Score: 0.023
  8. Fader AN, Nagel C, Axtell AE, Zanotti KM, Kelley JL, Moore KN, Secord AA, Walsh CS, Huh WK, Gehrig PA, Gibbons H, Rose PG, Havrilesky LJ, Tuller E, Drake RD, Bottsford-Miller J, O'Malley DM. Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes. Gynecol Oncol. 2009 Mar; 112(3):558-62.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)